Phase 3 Clinical Trials With Primary Completion Dates in April 2022

This is a list of Phase 3 trials with primary completion dates in April 2022 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
ASNDAscendis Pharma A/S2022-04-01Phase 3NCT04326374Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone Deficiency
CANFCan-Fite BioPharma Ltd.2022-04-01Phase 3NCT03168256CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis
DBVTDBV Technologies S.A.2022-04-01Phase 3NCT03211247Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age
GKOSGlaukos Corporation2022-04-01Phase 3NCT03519386Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%
GLYCGlycoMimetics, Inc.2022-04-01Phase 3NCT03616470Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia
KODKodiak Sciences Inc.2022-04-01Phase 3NCT04592419A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
KRTXKaruna Therapeutics, Inc.2022-04-01Phase 3NCT04659161A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)
MCRBSeres Therapeutics, Inc.2022-04-01Phase 3NCT03183141ECOSPOR IV: Open-Label Study, Including Study SERES-012 Extension, Evaluating SER-109 in Recurrent Clostridioides Difficile Infection
NEPHNephros, Inc.2022-04-01Phase 3NCT03534284Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis
OBSVObsEva SA2022-04-01Phase 3NCT04335591Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)
RIGLRigel Pharmaceuticals, Inc.2022-04-01Phase 3NCT04629703Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
RIGLRigel Pharmaceuticals, Inc.2022-04-01Phase 3NCT03764618A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA